$ACET is a BUY.
This producer of chemicals used in generic drugs is a recent addition to our IXTHYS Letter Portfolio. The company produces $545M in revenues and shares trade at a low 22x earnings, and 9x forward estimates. Net income has increased an average of 27% per year over the past 5 years. A 0.8x sales metric shows upside potential.
Zacks Research gives ACET a top rank of 1 (strong buy) for its recent upward revisions in earnings estimates.
Shares pay 1.6% dividend, and 10% of the float is short. We may see a squeeze in play when the company reports earnings on Thursday.
The chart shows a bullish base breakout in progress.